Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery - Reuters

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQVGRLQTBxRHVVMUNsX05aYmd5akMtUmhuVzcxN0lEbF9yLW5CNmtSVFZVT2pCWDV5bS1zM3BobDd3dVU3cXJSdjhyTkZSWW1fNGpKYlhReFg3M3I3Zy14VE9WMWpnNDQ4QWt3Q0h0enZOcUNuX01HTVNrRkFZTlNTVUlqLWczZUlMbnBhWDRJY3drN3BuVDlQMm5tUEJuNTZwRTNsWk1mZlhqdTdwcXJ1eVYzQU9QUENMVGJrS0hSLW1IYjRy?oc=5" target="_blank">Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1 billion led by Thrive Capital, after raising $600 million in its first round in March 2025.

Isomorphic Labs has raised $2.1 billion in a Series B financing led by Thrive Capital, with participation from the UK's Sovereign AI Fund, Abu Dhabi's MGX, Alphabet venture arm GV, and Singapore's Temasek.

Isomorphic Labs, an AI-driven drug discovery firm, has secured $2.1 billion in a Series B funding round led by Thrive Capital, with participation from Alphabet and other investors, to advance its AI drug design engine and in-house drug pipeline.

Isomorphic Labs, a subsidiary of Alphabet Inc., has raised $2.1 billion in its second round of outside capital, with new support from sovereign wealth funds, as it seeks to make artificial intelligence-designed drugs a reality.

Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, is in advanced discussions to raise more than $2 billion in a new funding round, according to Bloomberg.